地塞米松杂质 | 59860-99-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 地塞米松杂质
• 英文名称: 9α-fluoro-11β,21-dihydroxy-16-methylpregna-1,4,16-triene-3,20-dione
• 英文别名: Pregna-1,4,16-triene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-, (11beta)-；(8S,9R,10S,11S,13S,14S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15-hexahydro-6H-cyclopenta[a]phenanthren-3-one
• CAS: 59860-99-0
• 化学式: C₂₂H₂₇FO₄
• 分子量: 374.452
• InChiKey: PSXDNQUHAFMVPT-QEYSUVLUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  地塞米松杂质 以 四氢呋喃 、 水 为溶剂， 生成 9α-fluoro-11β-hydroxy-16-methyl-3-oxoandrosta-1,4,16-triene-17-carboxylic acid
  参考文献：
  名称：

  Chemical compounds

  摘要：

  该规范描述了具有公式##SPC1##的新型抗炎类固醇，其中R.sup.1代表C.sub.1-4烷基或卤代C.sub.1-4烷基，R.sup.2代表甲基、乙基、正丙基或异丙基（尤其是乙基），X代表氢、氯或氟原子，--代表单键或双键。该规范描述了制备这些化合物的过程以及含有这些化合物的药物组合物。

  公开号：

  US03981894A1

文献信息

• Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
  申请人：OCULIS EHF

  公开号：US11135311B2

  公开（公告）日：2021-10-05

  The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

  本公开涉及含有活性药物成分和环糊精固体复合物的眼科组合物、其制备方法和用途。这些组合物可以包括基本溶解在水性滴眼液载体中的活性药物/环糊精复合物。眼药组合物一般为微悬浮液形式，包括直径小于约 100 μm 的活性剂复合物。
• PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY
  申请人：Oculis SA

  公开号：EP3548091B1

  公开（公告）日：2021-12-01
• [EN] PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERY<br/>[FR] PRÉPARATION DE COMPLEXES SOLIDES DE CYCLODEXTRINE PERMETTANT UNE ADMINISTRATION DE SUBSTANCE PHARMACEUTIQUE ACTIVE OPHTALMIQUE
  申请人：OCULIS EHF

  公开号：WO2018100434A1

  公开（公告）日：2018-06-07

  The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 µm.
• Chemical compounds
  申请人：Glaxo Laboratories Limited

  公开号：US03981894A1

  公开（公告）日：1976-09-21

  The specification describes new anti-inflammatory steroids having the formula ##SPC1## Wherein R.sup.1 represents a C.sub.1-4 alkyl or halo- C.sub.1-4 alkyl group, R.sup.2 represents a methyl, ethyl, n-propyl or iso-propyl group (an ethyl group being especially preferred), X represents a hydrogen, chlorine or fluorine atom and -- represents a single or double bond. The specification describes processes for the preparation of such compounds as well as pharmaceutical compositions containing these compounds.

  该规范描述了具有公式##SPC1##的新型抗炎类固醇，其中R.sup.1代表C.sub.1-4烷基或卤代C.sub.1-4烷基，R.sup.2代表甲基、乙基、正丙基或异丙基（尤其是乙基），X代表氢、氯或氟原子，--代表单键或双键。该规范描述了制备这些化合物的过程以及含有这些化合物的药物组合物。